Universal Screening Programme for Cytomegalovirus Infection in the First Trimester of Pregnancy: Study Protocol for an Observational Multicentre Study in the Area of Barcelona (CITEMB Study)

Overview

Journal BMJ Open

Specialty General Medicine

Date 2023 Jul 20

PMID 37474185

Authors

Maria Angeles Sanchez-Duran

Nerea Maiz

Liudmila Liutsko

Jofre Bielsa-Pascual

Rosa Garcia-Sierra

Aneta Monika Zientalska

Ines Velasco

Eva Vazquez

Olga Gracia

Aleida Ribas

Nuria Sitja

Maria Nadales

Cristina Martinez

Anna Gonce

Marie Antoinette Frick

Mercedes Guerrero-Martinez

Concepcion Violan

Pere Toran

Gemma Falguera-Puig

Roser Gol

Affiliations

Soon will be listed here.

Abstract

Introduction: Congenital cytomegalovirus (cCMV) is the leading cause of non-genetic sensorineural hearing loss and one of the main causes of neurological disability. Despite this, no universal screening programme for cCMV has been implemented in Spain. A recent study has shown that early treatment with valaciclovir, initiated in the first trimester and before the onset of signs in the fetus, reduces the risk of fetal infection. This finding favours the implementation of a universal screening programme for cCMV.The aim of this study is to evaluate the performance of a universal screening programme for cCMV during the first trimester of pregnancy in a primary care setting.

Methods And Analysis: This is an observational multicentre cohort study. The study will be conducted in four primary care settings from the Northern Metropolitan Barcelona area and three related hospitals and will last 3 years and will consist of a recruitment period of 18 months.In their first pregnancy visit, pregnant women will be offered to add a CMV serology test to the first trimester screening tests. Pregnant women with primary infection will be referred to the reference hospital, where they will continue treatment and follow-up according to the clinical protocol of the referral hospital, which includes treatment with valacyclovir. A CMV-PCR will be performed at birth on newborns of mothers with primary infection, and those who are infected will undergo neonatal follow-up for at least 12 months of life.For the analysis, the acceptance rate, the prevalence of primary CMV infections and the CMV seroprevalence in the first trimester of pregnancy will be studied.

Ethics And Dissemination: Ethical approval was obtained from the University Institute Foundation for Primary Health Care Research Jordi Gol i Gurina Ethics Committee 22/097-P dated 27 April 2022.

Citing Articles

Recent HCMV infection in early pregnancy associates with congenital transmission & adverse pregnancy outcome: A prospective cohort study.

Palav H, Padwal V, Velhal S, Yadav S, Bhonde G, Kalsurkar V Indian J Med Res. 2025; 160(6):614-624.

PMID: 39913512 PMC: 11801775. DOI: 10.25259/IJMR_89_2024.

Maternal and congenital human cytomegalovirus infection: laboratory testing for detection and diagnosis.

Leber A J Clin Microbiol. 2024; 62(4):e0031323.

PMID: 38391188 PMC: 11005381. DOI: 10.1128/jcm.00313-23.

References

Harris P, Taylor R, Thielke R, Payne J, Gonzalez N, Conde J . Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2008; 42(2):377-81. PMC: 2700030. DOI: 10.1016/j.jbi.2008.08.010. View

Chatzakis C, Ville Y, Makrydimas G, Dinas K, Zavlanos A, Sotiriadis A . Timing of primary maternal cytomegalovirus infection and rates of vertical transmission and fetal consequences. Am J Obstet Gynecol. 2020; 223(6):870-883.e11. DOI: 10.1016/j.ajog.2020.05.038. View

Hughes B, Clifton R, Rouse D, Saade G, Dinsmoor M, Reddy U . A Trial of Hyperimmune Globulin to Prevent Congenital Cytomegalovirus Infection. N Engl J Med. 2021; 385(5):436-444. PMC: 8363945. DOI: 10.1056/NEJMoa1913569. View

Seror V, Leruez-Ville M, zek A, Ville Y . Leaning towards Cytomegalovirus serological screening in pregnancy to prevent congenital infection: a cost-effectiveness perspective. BJOG. 2021; 129(2):301-312. DOI: 10.1111/1471-0528.16966. View

Cannon M, Schmid D, Hyde T . Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Rev Med Virol. 2010; 20(4):202-13. DOI: 10.1002/rmv.655. View

Beaudoin M, Renaud C, Boucher M, Kakkar F, Gantt S, Boucoiran I . Perspectives of women on screening and prevention of CMV in pregnancy. Eur J Obstet Gynecol Reprod Biol. 2021; 258:409-413. DOI: 10.1016/j.ejogrb.2021.01.035. View

Leruez-Ville M, Foulon I, Pass R, Ville Y . Cytomegalovirus infection during pregnancy: state of the science. Am J Obstet Gynecol. 2020; 223(3):330-349. DOI: 10.1016/j.ajog.2020.02.018. View

Zuhair M, Smit G, Wallis G, Jabbar F, Smith C, Devleesschauwer B . Estimation of the worldwide seroprevalence of cytomegalovirus: A systematic review and meta-analysis. Rev Med Virol. 2019; 29(3):e2034. DOI: 10.1002/rmv.2034. View

de Vries J, van der Eijk A, Wolthers K, Rusman L, Pas S, Molenkamp R . Real-time PCR versus viral culture on urine as a gold standard in the diagnosis of congenital cytomegalovirus infection. J Clin Virol. 2011; 53(2):167-70. DOI: 10.1016/j.jcv.2011.11.006. View

10.

Suarez D, Nielson C, McVicar S, Sidesinger M, Ostrander B, OBrien E . Analysis of an Expanded Targeted Early Cytomegalovirus Testing Program. Otolaryngol Head Neck Surg. 2023; 169(3):679-686. DOI: 10.1002/ohn.320. View

11.

DAntonio F, Marinceu D, Prasad S, Khalil A . Effectiveness and safety of prenatal valacyclovir for congenital cytomegalovirus infection: systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2022; 61(4):436-444. DOI: 10.1002/uog.26136. View

12.

Pasternak B, Hviid A . Use of acyclovir, valacyclovir, and famciclovir in the first trimester of pregnancy and the risk of birth defects. JAMA. 2010; 304(8):859-66. DOI: 10.1001/jama.2010.1206. View

13.

Al Mana H, Yassine H, Younes N, Al-Mohannadi A, Al-Sadeq D, Alhababi D . The Current Status of Cytomegalovirus (CMV) Prevalence in the MENA Region: A Systematic Review. Pathogens. 2019; 8(4). PMC: 6963600. DOI: 10.3390/pathogens8040213. View

14.

Nance W, Lim B, Dodson K . Importance of congenital cytomegalovirus infections as a cause for pre-lingual hearing loss. J Clin Virol. 2005; 35(2):221-5. DOI: 10.1016/j.jcv.2005.09.017. View

15.

Gantt S, Dionne F, Kozak F, Goshen O, Goldfarb D, Park A . Cost-effectiveness of Universal and Targeted Newborn Screening for Congenital Cytomegalovirus Infection. JAMA Pediatr. 2016; 170(12):1173-1180. DOI: 10.1001/jamapediatrics.2016.2016. View

16.

De Santis M, Apicella M, De Luca C, Doria L, Valentini P, Sanguinetti M . Valacyclovir in primary maternal CMV infection for prevention of vertical transmission: A case-series. J Clin Virol. 2020; 127:104351. DOI: 10.1016/j.jcv.2020.104351. View

17.

Enders G, Daiminger A, Bader U, Exler S, Enders M . Intrauterine transmission and clinical outcome of 248 pregnancies with primary cytomegalovirus infection in relation to gestational age. J Clin Virol. 2011; 52(3):244-6. DOI: 10.1016/j.jcv.2011.07.005. View

18.

Izquierdo G, Sandoval A, Abarzua F, Yamamoto M, Rodriguez J, Silva M . [Recommendations for the diagnosis and management of cytomegalovirus infection in pregnant woman and newborn infant]. Rev Chilena Infectol. 2022; 38(6):824-856. DOI: 10.4067/s0716-10182021000600824. View

19.

Albright C, Werner E, Hughes B . Cytomegalovirus Screening in Pregnancy: A Cost-Effectiveness and Threshold Analysis. Am J Perinatol. 2018; 36(7):678-687. DOI: 10.1055/s-0038-1676495. View

20.

Retzler J, Hex N, Bartlett C, Webb A, Wood S, Star C . Economic cost of congenital CMV in the UK. Arch Dis Child. 2018; 104(6):559-563. DOI: 10.1136/archdischild-2018-316010. View